[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurological-diseases-or-conditions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurological-diseases-or-conditions":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,47,84,106,134,191,217,302,324,348,376,405,434,458],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100596078","natural-history-of-type-1-interferonopathies-insights-from-a-european-cohort-100596078",false,"NCT07040774","Natural History of Type 1 Interferonopathies: Insights From a European Cohort","EU-IFNp","Inclusion Criteria:\n\n* Genetically confirmed patient with type I interferonopathy\n* Patient affiliated to a social security scheme or beneficiary of such a scheme.\n\nExclusion Criteria:\n\n\\- Opposition of the patient and\u002For parental authority if the patient is a minor, to participation in the study.","ALL",{"count":18,"type":19},500,"ESTIMATED","OBSERVATIONAL","Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed.\n\nNearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear.\n\nIn this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies.\n\nThe main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies.\n\nThe overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.",[23,24,25,26],"Genetic Disease","Immune Dysfunction","Neurological Diseases or Conditions","Autoimmune Diseases",[28,29,30,31,32,33],"Immune dysfuntion","Neurological disease","Autoimmune diseases","Genetics diseases","Interferon","Aicardi-Goutieres Syndrom","RECRUITING","2026-05-12",{"date":37,"type":38},"2026-05-13","ACTUAL",{"date":40,"type":38},"2025-10-01",{"date":42,"type":19},"2045-10",{"name":44,"class":45},"Imagine Institute","OTHER",32,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100345405","cereset-research-exploratory-study-100345405","NCT03777267","Cereset Research Exploratory Study","Inclusion Criteria:\n\n* Subjects must have the ability to comply with basic instructions and be able to sit still comfortably with the sensor leads attached\n* Subjects experiencing symptoms of stress, anxiety, or insomnia, who meet threshold scores on one or more self-reported inventories for the same. This includes the Insomnia Severity Index (ISI, ≥ 8), the Perceived Stress Index (PSS, ≥ 14), or the Generalized Anxiety Disorder 7-item (GAD-7, ≥ 5) scale.\n\nExclusion Criteria:\n\n* Unable, unwilling, or incompetent to provide informed consent\u002Fassent.\n* Physically unable to come to the study visits, or to sit comfortably in a chair for up to 1.5 hours.\n* Severe hearing impairment (because the subject will be using ear buds during CR).\n* Weight is over the chair limit (285 pounds).\n* Currently in another active intervention research study.\n* Prior use of HIRREM, Brainwave Optimization, Cereset, or a wearable configuration of the same (B2, or B2v2) within the last 3 years.\n* Prior use of electroconvulsive therapy (ECT).\n* Prior use of transcranial magnetic stimulation (TMS), transcranial direct current stimulation (TDCS), alpha stimulation, neurofeedback, biofeedback, or deep brain stimulation (DBS) within one month before enrollment.\n* Known seizure disorder.","11 Years",{"count":55,"type":19},200,"INTERVENTIONAL",[58],"NA","The purpose of this study is to evaluate the use of Cereset Research to improve autonomic function in participants with symptoms of stress, anxiety, or insomnia.",[25,61,62],"Cardiovascular Conditions After Birth","Psychophysiologic Disorders",[64,65,66,67,68,69,70,71,72,73],"Stress","Neurotechnology","Autonomic Dysregulation","Hyperarousal","Brain electrical activity","Allostasis","HIRREM","Cereset Research","Insomnia","Anxiety","2026-04-28",{"date":76,"type":38},"2026-05-04",{"date":78,"type":38},"2019-04-12",{"date":80,"type":19},"2028-04",{"name":82,"class":45},"Wake Forest University Health Sciences",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":16,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":93,"studyType":20,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":83},"100554849","the-natural-history-of-mitochondrial-diseases-100554849","NCT06504433","The Natural History of Mitochondrial Diseases","Inclusion Criteria:\n\n1. A clinical and\u002For genetically confirmed diagnosis of MITO.\n2. Individuals \\> 18 years of age, managed by a specialist neurologist, with confirmed MITO\n3. Control participants will comprise asymptomatic relatives of confirmed MITO patients with no clinical or genetic evidence of MITO; clinically confirmed non-MITO movement disease controls (from other clinics at NeuRA) or age\u002Fgender-matched healthy participants.\n\nExclusion Criteria:\n\n* Those participants who do NOT match the inclusion criteria above\n* Not willing to participate in the AMDC Clinical Registry\n* Not willing to undergo genetic testing\n* Not willing to provide consent",true,"18 Years",{"count":18,"type":19},"10 Years","The Natural History of Mitochondrial (MITO) Diseases (a longitudinal study observing the natural history of mitochondrial diseases)\n\nThe goal of this observational study (non-randomised retrospective and prospective) is to fully characterise primary MITO disease; that includes both sexes\u002Fgenders, over 18 years of age and healthy volunteers\\]. The main question\\[s\\] it aims to answer is to:\n\n• better characterise MITO phenotypes (organ involvement, severity, progression) and collect biospecimens to create a biobank that can be used for future biomarker discovery to improve early diagnosis, prognostication and management of mitochondrial disease.\n\nThe study will be a longitudinal, retrospective, prospective, observational study of participants (400) with confirmed MITO and relevant controls followed for up to 10 years. Data will be collected at regularly scheduled standard-of-care (SOC), 6 to 12 monthly appointments.\n\nThe 100 control participants will therefore be comprised of (i) unaffected asymptomatic family members of MITO participants with no genetic risk; (ii) participants with non-MITO movement disorders that are not classified as MITO by their clinical presentation and genetic tests (for example Parkinson's disease) and\u002For (iii) age-matched healthy controls recruited from the NeuRA database of volunteers.\n\nDemographic data, medical history, biochemical, histological, genetic, social and other clinical SOC data will be collected. Additionally, seizure and migraine frequency in participants who experience these, will be collected and a quality-of-life questionnaire (SF-12v2), as part of the validated neurological assessment using the Newcastle Mitochondrial Disease Adult Scale (NMDAS).",[96,25,23],"Mitochondrial Diseases","2026-04-15",{"date":99,"type":38},"2026-04-20",{"date":101,"type":38},"2024-05-07",{"date":103,"type":19},"2034-05-07",{"name":105,"class":45},"Neuroscience Research Australia",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":90,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":112,"targetDuration":114,"studyType":20,"phases":4,"briefSummary":115,"conditions":116,"keywords":123,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":83},"100416731","archival-of-human-biological-samples-in-cu-med-biobank-100416731","NCT04706481","Archival of Human Biological Samples in CU-Med Biobank","Inclusion Criteria:\n\n* Enrolled subjects that have provided signed consent for the specimens and de-identified data to be collected, stored and distributed.\n\nExclusion Criteria:\n\n* Subjects without signed informed consent for the specimens and de-identified data to be collected, stored and distributed.",{"count":113,"type":19},10000,"99 Years","CU-Med Biobank collaborates with different researchers for collecting and distributing human biospecimens and clinical data for assisting scientific research.",[117,118,119,25,120,121,122],"Healthy","Cancer","Heart Diseases","Kidney Diseases","Diabetes","Other Disease",[124],"Biobanking","2026-03-11",{"date":127,"type":38},"2026-03-12",{"date":129,"type":38},"2020-01-01",{"date":131,"type":19},"2050-12-01",{"name":133,"class":45},"Chinese University of Hong Kong",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":56,"phases":144,"briefSummary":145,"conditions":146,"keywords":157,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":189,"locationsCount":83},"100612195","development-and-efficacy-of-a-novel-cost-effective-gait-training-device-utilized-at-home-for-stroke-survivors-100612195","NCT07250425","Development and Efficacy of a Novel, Cost-Effective Gait Training Device Utilized at Home for Stroke Survivors","Development of a Novel, Cost-Effective Gait Training Device Utilized at Home for the Neurological Patient Population","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* First-ever ischemic or hemorrhagic stroke confirmed by medical record.\n* 3 months to 5 years post-stroke at time of enrollment.\n* Presence of lower-extremity motor impairment limiting walking function.\n* Able to stand for at least 30 minutes with no more than minimal assistance (with or without a device).\n* Medically stable and cleared by a physician to participate in moderate-intensity ambulation exercise.\n* Living in a home environment that can safely accommodate device installation (e.g., adequate space, appropriate flooring, and power access) as determined by the study team.\n* Able to understand study procedures and provide informed consent (or have a legally authorized representative), with sufficient cognitive and communication skills to follow simple instructions.\n* If assistance is required for transfers or device set-up, availability of a caregiver or assistant willing to participate in training and device use.\n\nExclusion Criteria:\n\n* Unstable cardiovascular, respiratory, or other medical conditions that contraindicate moderate- to high-intensity walking exercise (e.g., unstable angina, decompensated heart failure, uncontrolled arrhythmias).\n* Severe musculoskeletal or orthopedic conditions limiting safe participation in supported stepping (e.g., unstable fractures, severe contractures preventing positioning in the device).\n* Severe spasticity or movement disorders that would preclude safe use of the device, based on investigator judgment.\n* Severe cognitive impairment, aphasia, or behavioral disturbance that would prevent informed consent or safe participation.\n* Progressive neurological conditions (e.g., progressive neurodegenerative disease) expected to significantly worsen over the 12-week study period.\n* Current participation in another interventional trial targeting gait or lower-extremity function.\n* Any other condition that, in the opinion of the investigators, would make participation unsafe or interfere with study adherence or outcome interpretation.","75 Years",{"count":143,"type":19},20,[58],"This pilot, parallel-group randomized controlled trial will evaluate the feasibility, safety, usability, and preliminary efficacy of the Rise\\&Walk InHome (RWH), a novel robotic gait training device designed for home use after stroke. Twenty adults with lower-extremity motor impairment following a first-ever stroke (3 months to 5 years post-event) will be randomized 1:1 to either (1) RWH-assisted home walking plus usual care or (2) usual care alone for 12 weeks. Participants in the intervention group will receive an in-home RWH device, complete a structured device training program, and be instructed to perform 30-minute RWH walking sessions four times per week (48 sessions total). All participants will undergo standardized outcome assessments at baseline, weeks 4, 8, and 12, including the 6-Minute Walk Test (primary outcome), 10-Meter Walk Test, daily step count via wearable activity tracker, and health-related quality of life (SF-36). Additional feasibility and usability outcomes include device use and adherence, patient satisfaction and motivation, ease of use, perceived exertion, and adverse events. Findings will inform the feasibility of in-home deployment of the RWH device and provide preliminary effect-size estimates to guide the design of a larger efficacy trial.",[147,25,148,149,150,151,152,153,154,155,156],"Stroke","Hemiparesis;Poststroke\u002FCVA","Gait Disorders, Neurologic","Post Stroke Fatigue","Motor Recovery","Walking Difficulty","Balance Impairment","Falls Prevention","Hemiparesis","Mobility Limitation",[158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181],"in-home rehabilitation","Robotic-Assisted Gait Training","gait training device","stroke recovery","functional mobility","rehabilitation technology","remote monitoring","rehabilitation robotics","Fitbit Step Tracking","Self-Directed Gait Training","high-intensity gait training","Neurorehabilitation Research","Lower Limb Rehabilitation","Motor Function Recovery","Physical Therapy","Walking Endurance","task specific walking practice","neurological recovery","stroke rehabilitation","home exercise program","Rise&Walk InHome","daily step count","6-minute walk test","10-meter walk test","NOT_YET_RECRUITING","2026-03-06",{"date":185,"type":38},"2026-03-09",{"date":187,"type":19},"2026-08",{"date":187,"type":19},{"name":190,"class":45},"Healing Innovations",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":56,"phases":202,"briefSummary":203,"conditions":204,"keywords":207,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":83},"100488814","transcranial-magnetic-stimulation-therapy-in-neuropathic-painful-spinal-cord-injury-patients-100488814","NCT05645003","Transcranial Magnetic Stimulation Therapy in Neuropathic Painful Spinal Cord Injury Patients","Effect of Repetative Transcranial Magnetic Stimulation Therapy on Neuropathic Pain in Patients With Spinal Cord Injury","Inclusion Criteria:\n\nBetween the ages of 20-70, who applied to the AFSU Physical Medicine and Rehabilitation inpatient service with the diagnosis of spinal cord injury and\n\n* Having spinal cord injury with neurophatic pain at least six months ago,\n* Able to follow two-stage verbal commands,\n* Agreeing to participate in the study voluntarily and regularly,\n* Patients who are medically stable (no previous myocardial infarction, no musculoskeletal problems) will be included in our study.\n\nExclusion Criteria:\n\nHaving an important comorbid disease such as severe heart disease (aortic stenosis, angina, hypertrophic cardiomyopathy, arrhythmia, pacemaker) and uncontrolled hypertension,\n\n* Epilepsy,\n* History of antiepileptic drug use,\n* Intracranial metal object,\n* Presence of in-ear implant,\n* Cognitive dysfunction,\n* Lower extremity peripheral nerve injury,\n* With malignancy and active infection,\n* Infection on the skin in the application area,\n* Having an open wound,\n* Having inflammatory disease,\n* Orthopedic injuries that can limit maximum effort contractions,\n* Having a brain lesion or a history of drug use that will affect the seizure threshold,\n* Patients with increased intracranial pressure or uncontrolled migraine will not be included.","20 Years","70 Years",{"count":201,"type":19},60,[58],"The aim of our study is to investigate the effect of high-frequency Repetitive Transcranial Magnetic Stimulation(rTMS) therapy applied to the dorsolateral PFC (DLPFC) area on neuropathic pain in patients with spinal cord injury. In this area, there are very few studies on the effectiveness of rTMS treatment added to medical treatment in neuropathic pain. In addition, the number of studies comparing the effect of rTMS therapy applied to the DLFPC area is very few.",[205,206,25],"Spinal Cord Injuries","Neuropathic Pain",[208,209],"Repetitive Transcranial Magnetic Stimulation","Neurological Rehabilitation",{"date":185,"type":38},{"date":212,"type":38},"2022-11-15",{"date":214,"type":19},"2026-03-31",{"name":216,"class":45},"Afyonkarahisar Health Sciences University",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":90,"sex":16,"minAge":224,"maxAge":4,"enrollmentInfo":225,"targetDuration":93,"studyType":20,"phases":4,"briefSummary":226,"conditions":227,"keywords":270,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":83},"100424417","unhide-project-a-digital-health-platform-to-collect-lifestyle-data-for-brain-inflammation-research-100424417","NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","Unhide® Project Also Known as The Unhide® Solve Together Unified Platform","Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions:\n\n* Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME\u002FCFS), and post-acute neuropsychiatric syndrome (PANS\u002FPANDAS).\n* Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.\n* Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.\n\nInflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis.\n\n* Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.\n* \"Healthy\" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members.\n* Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys.\n* Currently live in the United States\n* Be able to participate in English (stay tuned for updates about the Spanish language version)\n* Be willing to share symptom and health data through the platform","2 Years",{"count":113,"type":19},"The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. \"Healthy\" individuals without brain inflammation are also eligible to participate.\n\nThe digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.",[228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,26,25,267,268,269],"Post-Acute COVID-19 Syndrome","ME\u002FCFS","Rheumatic Arthritis","Juvenile Rheumatoid Arthritis (JRA)","Psoriatic Arthritis (PsA)","Ankylosing Spondylitis (AS)","Autoimmune Encephalitis","Celiac Disease","Celiac Disease in Children","Chronic Lyme Disease","Post-treatment Lyme Disease Syndrome","Crohn's Disease","Dysautonomia","Anorexia Nervosa","Bulimia Nervosa","ARFID","Avoidant \u002F Restrictive Food Intake Disorder","Ehlers Danlos Syndrome","Endometriosis","Fibromyalgia (FM)","Long COVID","Lupus","Migraines","Mast Cell Activation Syndrome","Multiple Sclerosis","Myalgic Encephalomyelitis (ME)","Myasthenia Gravis, Generalized","Myasthenia Gravis in Children","Narcolepsy","Obsessive Compulsive Disorder (OCD)","PANDAS","Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","POTS - Postural Orthostatic Tachycardia Syndrome","General Anxiety Disorder, Social Anxiety Disorder","PTSD - Post Traumatic Stress Disorder","Psoriasis","Traumatic Brain Injury","Tourette's Syndrome","Inflammatory Bowel Disease (IBD)","Psychiatric Disorder","Sjogren's Syndrome","Ulcerative Colitis and Crohn's Disease",[248,271,272,273,274,275,276,277,278,279,229,280,281,282,283,284,250,285,286,287,288,289,290,291,292],"Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Longitudinal Natural History Study","Observational","Neuroinflammatory Disease","Brain inflammation","Neuroinflammatory disorders","PANS\u002FPANDAS","Autoimmune encephalitis","Dysautonomia \u002F POTS","Multiple sclerosis","Autoimmune disease","Inflammatory bowel disease (Crohn's, ulcerative colitis)","Celiac disease","Mood disorders (anxiety, depression, bipolar, PTSD, OCD)","Mobile health app","Patient registry","Wearable devices","Fatigue","Post-exertional malaise","Brain Fog","Mental health","2026-01-20",{"date":295,"type":38},"2026-01-22",{"date":297,"type":38},"2023-07-05",{"date":299,"type":19},"2030-12-31",{"name":301,"class":45},"Brain Inflammation Collaborative",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":90,"sex":16,"minAge":91,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":323},"100612521","gel--medication-dysphagia-100612521","NCT07254663","GEL & MEDication Dysphagia","Influence of Swallow Gel and Semi-solid Consistency on Medication Dysphagia: A Multicenter Observational Study","GELMED","Inclusion Criteria:\n\nPatients:\n\nAdults with a dysphagia-associated disease (neurovascular, neurodegenerative, neuroinflammatory, or neuromuscular disorders; in other centers also ENT-related diseases), for whom FEES is clinically indicated.\n\nCapable of providing informed consent and cognitively able to follow the study protocol.\n\nHealthy Controls Adults without any dysphagia-associated disease (no neurovascular, neurodegenerative, neuroinflammatory, or neuromuscular disorders; no ENT-related diseases with structural abnormalities of the oropharynx or esophagus).\n\nCapable of providing informed consent and cognitively able to follow the study protocol.\n\nExclusion Criteria:\n\nNo additional exclusion criteria beyond those specified in the inclusion criteria.",{"count":18,"type":19},"This research project examines the prevalence of medication-related dysphagia in patients with dysphagia-associated diseases. Its primary aim is to assess how frequently swallowing difficulties occur during medication intake and to evaluate the impact of different consistencies-such as semi-solid formulations and commercial swallowing gels-on the swallowing process. Flexible endoscopic evaluation of swallowing serves as the diagnostic gold standard to determine whether alternative administration forms can facilitate safer swallowing. The findings are intended to support the optimization of medication intake and the prevention of complications in patients with dysphagia.",[25,313],"Healthy Participants","2025-11-26",{"date":316,"type":38},"2025-11-28",{"date":318,"type":38},"2025-09-15",{"date":320,"type":19},"2027-09-15",{"name":322,"class":45},"Heinrich-Heine University, Duesseldorf",3,{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":83},"100603838","collection-of-digital-parameters-from-parts-of-the-neurological-examination-using-an-eye-tracker-100603838","NCT07141719","Collection of Digital Parameters From Parts of the Neurological Examination Using an Eye Tracker","A Digital Protocol for Neurological Examination Using Eye-Tracking","NEX-Eye","Inclusion Criteria:\n\n* ≥ 18 years of age.\n* Diagnosed or treated for a neurological disease.\n* Hospitalized or outpatient of the Department of Neurology, UKSH Campus Kiel.\n* Ability of the person to understand oral study information and study information sheet, and willingness to provide a signed and dated informed consent form.\n\nExclusion criteria:\n\n* Being under legal guardianship\n* Impaired decision-making capacity, or temporal or spatial disorientation which may be revealed within ordinary conversation or by a confirmed diagnosis of dementia. In case of doubt, the Montreal Cognitive Assessment (MoCA, pass cutoff score \\> 18 16) will be administered.",{"count":333,"type":19},600,"The neurological examination (NE) is a cornerstone of clinical neurology, with ocular motor assessment being a key component. Technology offers an opportunity to augment and standardize parts of the NE. Eye-tracking systems provide objective quantitative data on eye movements by continuously tracking the eye over time. This data can be used to derive parameters like saccadic latency, gaze velocity, and fixation stability with a precision that is impossible to achieve through human observation by neurologists. The integration of such technology could enhance the traditional NE.\n\nBefore such technology can be widely adopted, its feasibility and acceptability in a clinical population must be established. The primary purpose of this study is to assess the usability of a novel eye-tracking system from the patient's perspective when used in a clinical settings. A secondary purpose is to determine if quantitative data from the eye-tracker correlate with the findings of the traditional clinical neurological examination and to explore whether eye-tracking can provide additional, complementary information not typically captured by standard clinical assessment.\n\nTo achieve these aims, the study will assess several outcome measures. The primary outcome measure is the Usability of the Eye-Tracking System, which will be measured using the System Usability Scale (SUS).\n\nBeyond the primary objectives, this study will investigate two secondary objectives.\n\nThe first involves assessing the relationship between quantitative eye-tracking parameters and clinical ocular motor assessment. Specifically, the investigators will analyze objective, numerical data obtained from eye-tracking systems and the clinician's subjectively graded assessment of ocular movements derived from the standard neurological examination.\n\nThe second is the exploratory analysis of novel eye-tracking biomarkers. This involves quantifying and analyzing eye-tracking parameters not typically assessed during a routine NE. For example, the dynamics of the pupillary light reflex or the frequency of microsaccades. The aim is to identify potential digital biomarkers that could provide additional objective insights into ocular motor function and neurological status.",[336,337,338,25],"Geriatric","Parkinsons Disease (PD)","Progressive Supranuclear Palsy(PSP)","2025-08-24",{"date":341,"type":38},"2025-08-26",{"date":343,"type":19},"2025-08-31",{"date":345,"type":19},"2026-12-31",{"name":347,"class":45},"University of Kiel",{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":56,"phases":359,"briefSummary":360,"conditions":361,"keywords":362,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":83},"100585330","transcranial-static-field-stimulation-tsms-and-transcranial-direct-current-stimulation-tdcs-for-the-treatment-of-neurological-symptoms-100585330","NCT06900959","Transcranial Static Field Stimulation (tSMS) and Transcranial Direct Current Stimulation (tDCS) for the Treatment of Neurological Symptoms.","Transcranial Static Field Stimulation (tSMS) and Transcranial Direct Current Stimulation (tDCS) for the Treatment of Neurological Symptoms","NIBS-tSMS\u002FtDCS","Inclusion Criteria:\n\n* Males or females aged between 18 and 80 years;\n* Presence of a neurological disorder, specifically the following conditions will be considered: MS, ALS, PD, AD, Dementias, TBI, neurosurgical interventions, stroke, fibromyalgia, epilepsy, headache, migraine, with at least one of the following symptoms: pain, neuropathic pain, neuralgias, depression, anxiety, apathy, fatigue, cognitive decline, aphasia, functional motor disorders (FMD), neuromuscular tone alterations, hyposthenia, involvement of multiple cognitive functions (including decision-making, problem-solving, learning, memory, executive functions, social and emotional cognition);\n* Patients must be able to follow the protocol instructions for the duration of the study;\n* Be able to understand the purposes and risks of the study;\n* Be able to understand and provide written informed consent to the study.\n\nExclusion Criteria:\n\n* Partial or total inability to understand or make decisions, inability to provide written informed consent for the study;\n* Patients with a history or presence of any unstable medical condition, such as neoplasms or infections;\n* Women with a positive pregnancy test at baseline or planning to become pregnant. Women who are breastfeeding or have given birth within the last three months prior to the start of the study;\n* Use of medications that increase the risk of seizures (e.g., Fampridine, 4-aminopyridine);\n* Concurrent use of medications that may alter synaptic transmission and plasticity (L-dopa, antiepileptics);\n* In the case of using NIBS techniques, subjects should not have any contraindications specific to this method (for further details, see the \"Methods\" and the \"Stimulation Assessment Questionnaire\" attached to this proposal).","80 Years",{"count":358,"type":19},40,[58],"The presence of damage to the central and\u002For peripheral nervous system resulting from various pathologies, such as Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), dementia, traumatic brain injury (TBI), stroke, or other neurological syndromes, is commonly a cause of both physical and mental disability. This leads to symptoms in the patient, including: pain, migraines, headaches, neuropathic pain, trigeminal neuralgia, depression, anxiety, apathy, fatigue, cognitive decline, aphasia, functional motor disorders (FMD), neuromuscular tone alterations, and hyposthenia, in addition to involvement of various cognitive functions, such as decision-making, problem-solving, learning, memory, executive functions, social cognition, and emotional cognition. The presence of these neurological symptoms is often evident in a first clinical examination and is one of the main reasons for further healthcare consultations. These difficulties have a profound impact on the quality of life, affecting work, social, and family functioning.\n\nIn recent years, several non-invasive brain stimulation (NIBS) techniques have emerged, aimed at eliciting brain neural networks, such as transcranial static magnetic field stimulation (tSMS) and transcranial direct current stimulation (tDCS).\n\ntSMS is an NIBS technique that involves the application of a neodymium magnet on the scalp. Since the first study proposing this method, several others have confirmed that tSMS can reduce corticospinal excitability. tDCS involves the application of weak electrical currents capable of generating an electric field that can modulate neural activity in an excitatory or inhibitory manner. NIBS techniques can be used experimentally to modulate cortical activity.\n\nThe primary aim of this proposal is to address the impact of neurological symptoms through the combination of tSMS with tDCS and rehabilitation techniques. Specifically, it aims to understand whether the combination of these neuromodulatory therapeutic NIBS methods can enhance symptom improvement in patients with neurological conditions.\n\nTo assess the impact of this intervention, a series of tests and questionnaires, described in detail below, will be used to evaluate the severity of the reported symptoms and secondary outcomes.\n\nMoreover, the contribution of specific brain areas to the symptom will be evaluated through the direct modulation of brain activity. This modulation will be achieved using an additional NIBS technique, such as Transcranial Magnetic Stimulation (TMS). TMS, in particular, is a non-invasive method for stimulating neurons in the brain's superficial areas, which has been frequently used in neurology as a diagnostic and research tool since its introduction. TMS uses magnetic fields to induce electrical currents capable of facilitating or inhibiting cortical activity.",[25],[363,364,365,366],"neuromodulation","non-invasive brain stimulation","transcranial direct current stimulation tDCS","transcranial static field stimulation tSMS","2025-03-22",{"date":369,"type":38},"2025-03-28",{"date":371,"type":19},"2025-05-11",{"date":373,"type":19},"2026-02-11",{"name":375,"class":45},"Neuromed IRCCS",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":56,"phases":386,"briefSummary":387,"conditions":388,"keywords":391,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":83},"100582124","new-technological-pathway-for-gait-rehabilitation-100582124","NCT06859229","New Technological Pathway for Gait Rehabilitation","Effects on Gait Patterns of a New Technological Pathway for Gait Rehabilitation in Patients With Movement Disorders","LABODIMOTO","Inclusion Criteria:\n\n* Patients with a Montreal Cognitive Assessment (MoCA) score, corrected for age and education, equal to or greater than 20.\n* Subjects capable of walking independently (Functional Ambulation Categories - FAC \\> 2).\n\nExclusion Criteria:\n\n* Cognitive impairments that compromise the understanding and\u002For execution of the proposed exercises.\n* Associated comorbidities that prevent maintaining an upright position or walking (e.g., hypotension).\n* Refusal or inability to provide informed consent.\n* Patients with contraindications to the use of the technological equipment required for the dynamic movement pathway.","60 Years",{"count":201,"type":19},[58],"\\*\\*Brief Summary\\*\\*\n\nThe study aims to explore how the integration of visual and motor systems can be trained and enhanced to improve gait rehabilitation in patients with various neurological and cardiovascular conditions. Scientific evidence highlights that physical activity requires coordination and precise processing of visual, auditory, and sensory information from the external environment, which is then integrated at the brain level. This process establishes synaptic connections that direct the movement of arms, hands, legs, and the trunk through bottom-up and top-down mechanisms. However, inaccurate or incomplete perceptual information can impair performance, even when accurate visual stimuli are provided, emphasizing the importance of assessing and enhancing visuo-motor integration.\n\nThe research investigates the central mechanisms controlling peripheral muscle activation patterns during gait. While over-ground walking in healthy individuals generally does not activate the prefrontal cortex except in dual-task scenarios, evidence suggests that post-stroke patients exhibit increased prefrontal cortex metabolism during walking. Recent studies have shown that gait training with exoskeletal systems improves walking patterns in post-stroke patients by altering muscle activation patterns and increasing fronto-parietal connectivity.\n\nThis study seeks to answer the following question: How do central and peripheral mechanisms interact to influence gait rehabilitation outcomes, and what role do visuo-motor integration and neuroplasticity play in this process? To address this, advanced neuroimaging technologies such as fMRI, dtMRI, and NIRS will be employed to investigate these mechanisms in vivo.",[25,389,390],"Cardiovascular Diseases","Neuromuscular Disease",[392,393,394,395],"neurorehabilitation","gait rehabilitation","analysis of movement","neuroplasticity","2025-03-04",{"date":398,"type":38},"2025-03-05",{"date":400,"type":19},"2025-03",{"date":402,"type":19},"2027-02",{"name":404,"class":45},"IRCCS Centro Neurolesi Bonino Pulejo",{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":56,"phases":415,"briefSummary":416,"conditions":417,"keywords":418,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":4},"100574760","measuring-single-neuron-activity-in-the-brain-100574760","NCT06763471","Measuring Single Neuron Activity in the Brain","Single Unit Neurophysiological Architecture of the Neocortex (SUNAN)","SUNAN","1. Aged 18 years and over.\n2. Documented informed consent to participate.\n3. Undergoing a transcranial neurosurgical procedure at the National Hospital for Neurology and Neurosurgery (NHNN) in which part of the cerebral cortex will be:\n\n   * Resected e.g., as removal of part of a tumour or epilepsy focused. Or\n   * Transgressed as part of the surgical approach to reach a deeper target e.g., resection of a deep tumour or cavernoma.\n\n   Or\n\n   • Transgressed by the passage of a surgical implant e.g., a ventriculoperitoneal shunt catheter or deep brain stimulation electrode.\n4. Surgery felt to be technically suitable for the neurophysiological recording technique by the Chief Investigator and responsible Consultant Neurosurgeon. For example, participants having surgery in an unusual position may present problems for the neurophysiological recording step.\n\nExclusion Criteria:\n\n1. Participants who lack the capacity to give informed consent.\n2. Participants who are pregnant or breast feeding at the time of surgery.\n3. Participants deemed to be unsuitable for recruitment to the study by the responsible Consultant Neurosurgeon. If in the view of the treating consultant involvement in the study would compromise the patient's surgery or present an unacceptable risk to them, they will not be recruited to the study. For example, if the participant does not meet the standard of care preoperative checks.\n4. Concern from the Consultant Neurosurgeon or treating Anaesthetist that there would be an unreasonable burden on the patient to participate in the study. For example, risk due to increased length of anaesthetic time.\n5. For participants requiring anaesthesia for their pre-planned brain surgery, an American Society of Anaesthesiologists (ASA) physical status classification system score of 4 and higher.\n6. Participants unable to understand English sufficiently well to read the patient facing documents and consent in English.\n7. Participants not undergoing their treatment through National Health Service (NHS) care (i.e. private patients are excluded).",{"count":414,"type":19},50,[58],"The SUNAN (Single Unit Neurophysiological Architecture of the Neocortex) study aims to understand how individual brain cells called neurons interact and communicate, and how the neurons can be affected in neurological disease. Using an advanced digital probe called the \"Neuropixels probe,\" which is as thin as a human hair, the investigators can record electrical activity from individual neurons on the outmost layer of the brain (cerebral cortex). This electrical (neurophysiological) activity recording technique allows the investigators to isolate and monitor single-neuron activity from the human brain during planned neurosurgical operations in real time.",[25],[419,420,421,422,423,424],"Neuron activity","Single unit","Neurosurgery","Neuropixels","Neurophysiology","Cortical","2025-01-06",{"date":427,"type":38},"2025-01-08",{"date":429,"type":19},"2025-02",{"date":431,"type":19},"2028-02",{"name":433,"class":45},"University College, London",{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":4},"100500421","an-observational-study-of-patients-living-with-chronic-neurological-diseases-100500421","NCT05796037","An Observational Study of Patients Living With Chronic Neurological Diseases","Disease Cohort\n\nInclusion Criteria:\n\n•Adult patients at the time of enrollment with a diagnosis of ADRD, MCI, PD, or MS by select ICD-10 codes in the EHR interface\n\nExclusion Criteria:\n\n* Death\n* Manual removal (sponsor or site request)\n* No EHR interface encounter \\> 3 years\n\nEngaged Cohort\n\nInclusion Criteria:\n\n* Adult patients diagnosed and managed for these conditions invited to participate\n* Ability to provide written informed consent (or have a legally authorized representative to provide informed consent)\n* Care partners may be invited to participate in surveys and will provide informed consent.\n\nExclusion Criteria:\n\n* Patient expressed desire to withdraw consent to complete PROs\n* Care partner expressed desire to withdraw consent to complete PROs\n* Failure to complete PROs within 24 weeks of initial invitation\n* Greater than 24 months lapse of survey completion after baseline surveys completed\n* Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort\n\nAge Cohort\n\nInclusion Criteria:\n\n•Adult patients aged 60 and older at time of enrollment\n\nExclusion Criteria:\n\n* Death\n* Manual removal (sponsor or site request)\n* No EHR interface encounter \\> 3 years",{"count":441,"type":19},1500000,"TARGET-NEURO is an observational research study to conduct a comprehensive review of outcomes for patients living with chronic neurological diseases: Alzheimer's disease and related dementia (ADRD), mild cognitive impairment (MCI), Parkinson's disease (PD), and multiple sclerosis (MS).",[25,444,445,446,447,252],"Dementia of Alzheimer Type","Alzheimer Disease","Mild Cognitive Impairment","Parkinson Disease","2024-11-18",{"date":450,"type":38},"2024-11-20",{"date":452,"type":19},"2025-03-31",{"date":454,"type":19},"2038-12-31",{"name":456,"class":457},"Target PharmaSolutions, Inc.","INDUSTRY",{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":90,"sex":16,"minAge":91,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":56,"phases":466,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":83},"100428990","prevalence-of-gag-reflex-in-healthy-persons-and-across-different-patient-groups-and-its-relevance-in-dysphagia-screening-100428990","NCT04866251","Prevalence of Gag Reflex in Healthy Persons and Across Different Patient Groups and Its Relevance in Dysphagia Screening","Inclusion Criteria:\n\n* informed consent\n\nExclusion Criteria:\n\n1. Healthy participants:\n\n   Neurological diseases Pre-diagnosed dysphagia Percutaneous endoscopic gastrostomy (PEG) tube Head and neck tumours Chemo- and\u002For radiotherapy in the head and neck area Reflux disease Chronic obstructive pulmonary disease (COPD) Previous surgeries on the cervical spine or thyroid gland Vocal cord paresis\n2. Geriatric patients Neurologic diseases\n3. Stroke patients Head and neck tumours Chemo- and\u002For radiotherapy in the head and neck area Reflux disease COPD Previous surgeries on the cervical spine or thyroid gland Vocal cord paresis\n4. Neurologic patients without stroke Head and neck tumours (except of intracranial tumors= Chemo- and\u002For radiotherapy in the head and neck area Reflux disease COPD Previous surgeries on the cervical spine or thyroid gland Vocal cord paresis",{"count":465,"type":19},700,[58],"The aim of this study is to assess the prevalence of gag reflex in healthy young and healthy older subjects as well as in acute stroke patients, in patients with Parkinsons´s Disease, Myasthenia gravis, Multiple Sclerosis and in geriatric patients.",[25],"2024-07-04",{"date":471,"type":38},"2024-07-08",{"date":473,"type":38},"2016-08-10",{"date":475,"type":19},"2024-07-01",{"name":477,"class":45},"University of Giessen"]